Fund Peregrine Pharmaceutical to Test Bavi for Herpes
2,077 Letters Sent So Far
Up to 50 million or one out of six United States citizens, 14 to 49 years of age have genital herpes simplex virus 2 (HSV-2) infection. Genital herpes increases oneís chances of acquiring HIV threefold.
As many as 90% of the United States population are impacted by herpes simplex virus 1 (HSV-1) oral/facial herpes commonly referred to as Cold Sores. Oral/facial herpes can and does lead to blindness and has been linked to Alzheimerís disease.
Amazingly, with a huge percentage of our population affected, there havenít been any new pharmaceutical treatments for herpes, post Valtrex, which has been 30 years!
Peregrine Pharmaceuticals located in Tustin, California is testing their broad spectrum antiviral, Bavituximab, for a variety of conditions. Their research and testing is being largely funded by the United States Department of Defense Ė which I as US taxpayer support. Peregrine has gone on record stating that Bavituximab may be an excellent treatment or cure for the herpes simplex virus (source http://www.thefreelibrary.com/Data+Published+in+Nature+Medicine+Highlights+Ability+of+Peregrine...-a0189645865). However, they indicate they do not have funding to test this promising drug for herpes.
As a US citizen, taxpayer, and concerned citizen, I plead with you to provide additional funding to Peregrine to facilitate their testing of Bavituximab for herpes simplex virus. Thank you so much for your service to our great country and your care for the millions of citizens suffering largely in silence.
May God Bless you, the sufferers and the United States of America!